Reply to Fernández-Fernández
Dr Fernandez-Fernandez 1 is right in raising the important new data regarding anti-angiogenic strategies in hereditary haemorrhagic telangiectasia (HHT), data which were published too late for inclusion in our review. 2 Although the gene mutations inform us that HHT is a disorder caused by aberrant signalling by the transforming growth factor (TGF)-b superfamily, the context in which the gene mutations are deleterious, when functioning apparently perfectly well for the vast majority of vessels, has always proved tantalising. In 2009, there has been a resurgent interest in the role of angiogenesis in provoking or unmasking an HHT phenotype, with animal models particularly implicating a role for aberrant angiogenesis during wound healing. 3 Pathogenesis-based treatment strategies based on case reports using anti-VEGF (bevacizumab/Avastin), [4] [5] [6] interferon, 7, 8 and thalidomide 9, 10 are being assessed in ongoing clinical trials at HHT centres. For any efficacious agent, sideeffect profiles are likely to be crucial in determining whether the use of any efficacious agents can become more widespread within the HHT patient population. In 2009, encouraging data were also reported for two better-tolerated agents, N-acetyl cysteine (trial data for 600 mg tds) 11 and tamoxifen (randomised placebo-control trial data for 20 mg/ day). 12 These have been introduced into specialised HHT practice, reflecting the rapidly advancing field. Govani and Shovlin 1 recently described the clinical and diagnostic implications of hereditary haemorrhagic telangiectasia (HHT). The authors 1 do not seem to be paying attention to the possible presence of genetic thrombophilic risk in HHT patients in relation to pharmacological treatment. Recently, we published 2 a case of HHT and genetic thrombophilia with pharmacological complications attributed to the coexistence of both genetic conditions. In the review paper, the authors 1 also highlight the risks of life-threatening maternal complications in pregnant HHT women. It is well known that up to 65% of vascular gestational abnormalities can be accounted for by genetic thrombophilias. 3 Therefore, it is possible that women with HHT may have recurrent pregnancy loss or other pregnancy complications because of to thrombophilic gene mutations. In the presence of thrombophilic risk, therapy with acetylsalicylic acid and low molecular heparin is recommended, but this may increase the risk of haemorrhages in the presence of HHT. To our knowledge, there are no data on the incidence of pregnancy complications, such as fetal loss or venous thrombosis, in HHT patients. As reported by Undas et al., 4 in the absence of life-threatening haemorrhages and detectable vascular malformations, oral anticoagulation could be considered with strictly haematological and clinical follow-up. An associated thrombotic tendency may confer a survival advantage for HHT patients by decreasing the severity of their bleeding problems. 5 We suggest that for the clinical management of these patients, genetic tests and counselling for inherited thrombophilia may be useful to prevent vascular and pregnancy complications and that more appropriate pharmacological treatment in consideration of the possible presence of both genetic conditions is used. 2 we did not have space to discuss in detail all of the implications of the cited studies, including, of relevance here, our large thrombosis 3 and pregnancy 4 HHT data series (EJHG references 9 and 48).
Reply to Bianca et al
Concern regarding thrombophilic risk in HHT patients in relation to pharmacological treatment was one of the main conclusions of our cited (EJHG reference 9) series of 309 HHT-affected individuals. 3 
